A detailed history of Van Hulzen Asset Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Van Hulzen Asset Management, LLC holds 205,634 shares of ABBV stock, worth $41.2 Million. This represents 2.37% of its overall portfolio holdings.

Number of Shares
205,634
Previous 192,846 6.63%
Holding current value
$41.2 Million
Previous $35.1 Million 0.44%
% of portfolio
2.37%
Previous 2.32%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $1.98 Million - $2.31 Million
12,788 Added 6.63%
205,634 $35.3 Million
Q1 2024

May 06, 2024

SELL
$159.82 - $182.1 $556,653 - $634,254
-3,483 Reduced 1.77%
192,846 $35.1 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $623,878 - $702,633
-4,534 Reduced 2.26%
196,329 $30.4 Million
Q3 2023

Nov 07, 2023

SELL
$133.59 - $154.65 $37,939 - $43,920
-284 Reduced 0.14%
200,863 $29.9 Million
Q2 2023

Aug 03, 2023

BUY
$132.51 - $164.9 $514,403 - $640,141
3,882 Added 1.97%
201,147 $27.1 Million
Q1 2023

Apr 28, 2023

BUY
$144.61 - $166.54 $5.92 Million - $6.82 Million
40,954 Added 26.2%
197,265 $31.4 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $1.16 Million - $1.39 Million
8,357 Added 5.65%
156,311 $25.2 Million
Q3 2022

Nov 08, 2022

SELL
$134.21 - $153.93 $3.7 Million - $4.24 Million
-27,565 Reduced 15.7%
147,954 $19.9 Million
Q2 2022

Aug 04, 2022

SELL
$137.62 - $174.96 $1.8 Million - $2.28 Million
-13,052 Reduced 6.92%
175,519 $26.9 Million
Q1 2022

May 20, 2022

BUY
$131.98 - $163.75 $484,102 - $600,635
3,668 Added 1.98%
188,571 $30.6 Million
Q4 2021

Feb 04, 2022

BUY
$107.43 - $135.93 $7.82 Million - $9.89 Million
72,784 Added 64.92%
184,903 $25.1 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $47,560 - $53,988
447 Added 0.4%
112,119 $12.1 Million
Q2 2021

Aug 06, 2021

BUY
$105.21 - $117.21 $441,040 - $491,344
4,192 Added 3.9%
111,672 $12.6 Million
Q1 2021

May 12, 2021

SELL
$102.3 - $112.62 $626,689 - $689,910
-6,126 Reduced 5.39%
107,480 $11.6 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $564,476 - $762,102
-7,013 Reduced 5.81%
113,606 $12.2 Million
Q3 2020

Nov 03, 2020

SELL
$85.91 - $100.83 $820,698 - $963,228
-9,553 Reduced 7.34%
120,619 $10.6 Million
Q2 2020

Aug 11, 2020

SELL
$73.37 - $98.18 $792,616 - $1.06 Million
-10,803 Reduced 7.66%
130,172 $12.8 Million
Q1 2020

May 14, 2020

BUY
$64.5 - $97.79 $352,750 - $534,813
5,469 Added 4.04%
140,975 $10.7 Million
Q4 2019

Feb 12, 2020

SELL
$72.13 - $90.25 $728,585 - $911,615
-10,101 Reduced 6.94%
135,506 $12 Million
Q3 2019

Oct 30, 2019

BUY
$62.98 - $75.72 $1.92 Million - $2.31 Million
30,551 Added 26.55%
145,607 $11 Million
Q2 2019

Aug 08, 2019

BUY
$65.7 - $83.98 $5.5 Million - $7.03 Million
83,703 Added 266.97%
115,056 $8.37 Million
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $547,385 - $644,245
-7,096 Reduced 18.46%
31,353 $2.53 Million
Q4 2018

Feb 12, 2019

BUY
$77.85 - $96.01 $395,166 - $487,346
5,076 Added 15.21%
38,449 $3.55 Million
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $354,395 - $393,976
3,986 Added 13.56%
33,373 $3.16 Million
Q2 2018

Aug 07, 2018

BUY
$89.78 - $106.23 $793,296 - $938,648
8,836 Added 43.0%
29,387 $2.72 Million
Q1 2018

May 08, 2018

SELL
$92.01 - $123.21 $97,990 - $131,218
-1,065 Reduced 4.93%
20,551 $1.95 Million
Q4 2017

Feb 12, 2018

SELL
$89.56 - $98.21 $3.18 Million - $3.48 Million
-35,461 Reduced 62.13%
21,616 $2.09 Million
Q3 2017

Nov 09, 2017

SELL
$69.85 - $89.22 $774,636 - $989,449
-11,090 Reduced 16.27%
57,077 $5.07 Million
Q2 2017

Aug 14, 2017

BUY
N/A
68,167
68,167 $4.94 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Van Hulzen Asset Management, LLC Portfolio

Follow Van Hulzen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Hulzen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Van Hulzen Asset Management, LLC with notifications on news.